{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Chen GY"],"pubmed_abstract":["Precocious puberty (PP) is a common condition among children. According to the pathogenesis and clinical manifestations, PP can be divided into central precocious puberty (CPP, gonadotropin dependent), peripheral precocious puberty (PPP, gonadotropin independent), and incomplete precocious puberty (IPP). Identification of the variations in key metabolites involved in CPP and their underlying biological mechanisms has increased the understanding of the pathological processes of this condition. However, little is known about the role of metabolite variations in the drug treatment of CPP. Moreover, it remains unclear whether the understanding of the crucial metabolites and pathways can help predict disease progression after pharmacological therapy of CPP. In this study, systematic metabolomic"],"journal":["Frontiers in molecular neuroscience"],"pagination":["972297"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9912178"],"repository":["biostudies-literature"],"pubmed_title":["Serum metabolomic analysis reveals key metabolites in drug treatment of central precocious puberty in female children."],"pmcid":["PMC9912178"],"pubmed_authors":["Xu ZC","Wang LQ","Tan HL","Sun JY","Wang LZ","Li Q","Jin YS","Liu JC","Yu DJ","Cui Y","Liu C","Wang LL","Chen GY"],"additional_accession":[]},"is_claimable":false,"name":"Serum metabolomic analysis reveals key metabolites in drug treatment of central precocious puberty in female children.","description":"Precocious puberty (PP) is a common condition among children. According to the pathogenesis and clinical manifestations, PP can be divided into central precocious puberty (CPP, gonadotropin dependent), peripheral precocious puberty (PPP, gonadotropin independent), and incomplete precocious puberty (IPP). Identification of the variations in key metabolites involved in CPP and their underlying biological mechanisms has increased the understanding of the pathological processes of this condition. However, little is known about the role of metabolite variations in the drug treatment of CPP. Moreover, it remains unclear whether the understanding of the crucial metabolites and pathways can help predict disease progression after pharmacological therapy of CPP. In this study, systematic metabolomic","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-25T19:25:55.137Z","creation":"2025-04-06T07:56:45.737Z"},"accession":"S-EPMC9912178","cross_references":{"pubmed":["36776772"],"doi":["10.3389/fnmol.2022.972297"]}}